Study Overview

A retrospective observational study published recently examined the impact of single antiplatelet​ therapy (SAPT) versus dual antiplatelet therapy (DAPT) following valve-in-valve transcatheter aortic valve ⁤implantation (TAVI). The study, conducted across 10 centers between ⁤January 2008 adn July 2023, included 278 patients. Researchers, led by Francesco Benandi, MD, found no significant difference in ​major adverse cardiac and cerebrovascular events (MACCE), major bleeding, or mortality between the two treatment groups.

study Details & Patient Characteristics

The study excluded patients receiving oral anticoagulant therapy. Of the 278 participants, 113 received SAPT ​and 165 received DAPT. Notably, the DAPT⁣ group exhibited several key ⁢differences compared to the SAPT group: they​ were, on average, older, had a higher prevalence ‌of hypertension⁢ and obstructive‍ coronary artery disease, and presented with a higher surgical risk score​ according to the Society of Thoracic Surgeons ‌(STS) criteria. The ‌STS⁢ score is a widely used tool‌ to assess ⁣the predicted risk of mortality and morbidity associated with cardiac surgery (Society of ⁢Thoracic Surgeons).

Clopidogrel was the predominant ⁤P2Y12 inhibitor used in the ‍DAPT group (99% of patients), while aspirin was the primary antiplatelet agent in the SAPT group​ (95%‌ of patients).

Key Findings: One-Year ⁣Follow-Up

After one year of follow-up, researchers analyzed both clinical and echocardiographic outcomes. The study revealed:

• MACCE: No ​significant⁤ difference was observed (Hazard Ratio [HR] 0.499; p=0.187).
• Major Bleeding: No significant difference was found (HR 0.776; p=0.741).
• All-cause ‍Death: No significant difference was observed (HR 0.907; p=0.874).
• Structural Valve Deterioration: No significant difference in moderate or severe deterioration was detected.
• Stroke: Patients treated with DAPT experienced a significantly lower incidence of stroke (HR 0.093; p=0.033).
• Minor Bleeding: Minor⁢ bleeding events were more frequent in the DAPT group.

Implications and Future ​Research

The authors conclude that while DAPT may‌ offer a protective effect against stroke in ⁤this patient population, further inquiry is warranted. They emphasize the need for larger studies to confirm thes findings, particularly regarding the potential benefits ‍of DAPT in preventing‍ stroke and premature valve degeneration. The study highlights the ongoing challenge of ⁣balancing the risks of bleeding with the need for effective antithrombotic therapy in patients undergoing valve-in-valve TAVI.